Nikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, George Morales, Rahnuma Beheshti, Paibel Aguayo-Hiraldo, Monzr M Al Malki, Francis Ayuk, Peter Bader, Janna Baez, Alexandra Capellini, Hannah Choe, Zachariah DeFilipp, Matthias Eder, Gilbert Eng, Aaron Etra, Sigrun Gleich, Stephan A Grupp, Elizabeth Hexner, Matthias Hoepting, William J Hogan, Stelios Kasikis, Nikolaos Katsivelos, Alina Khan, Carrie L Kitko, Sabrina Kraus, Deukwoo Kwon, Pietro Merli, Joseph Portelli, Muna Qayed, Ran Reshef, Tal Schechter, Ingrid Vasova, Matthias Wölfl, Kitsada Wudhikarn, Rachel Young, Ernst Holler, Yi-Bin Chen, Ryotaro Nakamura, John E Levine, James L M Ferrara
The overall response (ORR) rate 28 days after treatment has been adopted as the primary endpoint for clinical trials of acute graft versus host disease (GVHD). However, physicians often need to modify immunosuppression earlier than day (D) 28, and non-relapse mortality (NRM) does not always correlate with ORR at D28. We studied 1144 patients that received systemic treatment for GVHD in the Mount Sinai Acute GVHD International Consortium and divided them into a training set (n=764) and a validation set (n=380)...
February 4, 2024: Transplantation and cellular therapy